NY-FGS-GLOBAL
21.11.2023 14:01:39 CET | Business Wire | Press release
FGS Global announced today that it has acquired Longview Communications and Public Affairs, bringing together two of the world’s leading communications and public affairs advisory firms. FGS will now be able to serve clients more extensively throughout North America, with a deeply experienced team across eight offices in the United States and three offices in Canada. FGS’s approximately 1,300 professionals around the world offer an integrated suite of capabilities, with deep local relationships and extensive knowledge across industries and geographies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231121931472/en/
Celebrating its 20th anniversary this year, Longview is the Canadian market leader, advising clients on corporate and financial communications, issues and crisis management, special situations, government relations, regulatory affairs and foreign direct investment approvals. Consistently ranked among the top 15 global PR advisors on M&A and shareholder activism, Longview advises a wide range of leading Canadian companies, as well as numerous global companies operating across the country. Its team of over 30 professionals brings extensive experience and relationships at the highest levels of government, media and business, and provides the firm’s clients an integrated service offering across disciplines that is unmatched in Canada.
Winnie Lerner, FGS’s Chief Executive Officer, North America, said, “Longview is the go-to team on all mission critical issues for companies in Canada. The firm has an outstanding track record, deep client relationships, and values aligned with our own. Extending our reach into Canada broadens our geographic footprint and enhances our ability to deliver for our clients. We have known and respected Longview for a long time, have partnered successfully on many prior client assignments and are thrilled to welcome them to FGS.”
Josh Pekarsky, Founder and Managing Partner at Longview, said, “Longview has always been about doing great work for our clients. This transaction furthers that goal and provides an exceptional platform for the future. We have been impressed by the quality and thoughtfulness of what FGS is building and are delighted to become part of this leading global platform as we embark on this next chapter of our growth. Together with FGS, we are better equipped than ever to guide our clients through an increasingly complex world and a rapidly evolving stakeholder, financial, regulatory and political environment.”
Longview has been renamed FGS Longview and will continue to be led by Longview Partners Josh Pekarsky, Bruce Drysdale, Ian Hamilton and Hugh McFadyen. FGS Longview has offices in Toronto, Vancouver and Calgary, as well as team members in Ottawa, Winnipeg, Montreal and Victoria.
Andrew Cole, FGS’s Deputy Global Chief Executive Officer, added, “FGS was created to help leaders succeed in increasingly complex stakeholder ecosystems across industries and geographies. Clients want a strategic communications and advocacy partner who can advise and execute across the inter-connected financial, media, regulatory, and employee audiences in their home country and across the globe. We’re excited to partner with the Longview team and together help clients succeed in Canada and around the world.”
About Longview
Longview is Canada’s leading corporate communications and public affairs firm, with a seasoned team of professionals working together across disciplines to serve our clients’ interests. Our strategy is simple: do good work. Longview is top ranked in Canada, and the only Canadian firm consistently ranked among the top 15 PR advisors globally, on M&A transactions and shareholder activism. Longview serves clients from seven locations across Canada. The firm’s practice areas include Corporate & Financial Communications, Public Affairs, Special Situations and Design & Branding.
About FGS Global
FGS Global is a leading global strategic communications consultancy, with approximately 1,300 professionals around the world, advising clients in navigating complex situations and reputational challenges. FGS Global was formed from the combination of Finsbury, The Glover Park Group, Hering Schuppener and Sard Verbinnen to offer board-level and c-suite counsel in all aspects of strategic communications — including corporate reputation, crisis management, government affairs and is also the leading force in financial communications worldwide. The firm is backed by WPP Plc and KKR & Co. Inc.
FGS Global offers seamless and integrated support with offices in the following locations: Abu Dhabi, Amsterdam, Beijing, Berlin, Boston, Brussels, Chicago, Dubai, Dublin, Düsseldorf, Frankfurt, Hong Kong, Houston, Kingston, London, Los Angeles, Munich, Paris, Riyadh, San Francisco, Shanghai, Singapore, Tokyo, Washington, D.C., South Florida, and Zurich. Its headquarters is in New York.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231121931472/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom